Table I.
Relationship between the IGF1R expression and clinicopathological characteristics.
| Variables | No. of patients | IGF1R expression
|
|
|---|---|---|---|
| Positive n (%) | Negative n | ||
| Total patients | 182 | 43 (23.6) | 139 |
| Gender | |||
| Male | 100 | 25 (25.0) | 75 |
| Female | 82 | 18 (22.0) | 64 |
| Age (years) | |||
| <68 | 74 | 18 (24.3) | 56 |
| ≥68 | 108 | 25(23.1) | 83 |
| Pathologic stage | |||
| IA | 105 | 24 (22.9) | 81 |
| IB–III | 77 | 19 (24.7) | 58 |
| T status | |||
| T1a | 76 | 19 (25.0) | 57 |
| T1b–4 | 106 | 24 (22.6) | 82 |
| N status | |||
| Negative | 151 | 33 (21.9) | 118 |
| Positive | 31 | 10 (32.3) | 21 |
| Smoking history | |||
| Never | 75 | 18 (24.0) | 57b |
| Former | 50 | 11 (22.0) | 39 |
| Current | 57 | 14 (24.6) | 43 |
| Tumor gradea | |||
| G1 | 94 | 20 (21.3) | 74c |
| G2 | 59 | 16 (27.1) | 43 |
| G3 | 15 | 3 (20.0) | 12 |
| CEAc | |||
| <2.5 | 123 | 28 (22.8) | 95 |
| ≥2.5 | 57 | 15 (26.3) | 42 |
| SCCa | |||
| <1.5 | 140 | 34 (24.3) | 106 |
| ≥1.5 | 28 | 5 (17.9) | 23 |
| CYFRAa | |||
| <2.0 | 104 | 24 (23.1) | 80 |
| ≥2.0 | 74 | 19 (25.7) | 55 |
a
Unclassified patients were excluded;
b
never vs. former/current;
c
G1 vs. G2–3.